ACTA has been distributing key guidance, information and resources relevant to clinical trials during the COVID-19 pandemic.
COVID-19 communication has been distributed through our Newsletter list, so if you receive this newsletter directly, you will also be receiving our COVID-19 communications. To ensure you and your colleagues are seeing information as soon as it becomes available, please share our newsletters among your peers and encourage your colleagues to join our mailing list for updates using the link below.
Sign up to ACTA’s mailing list
We also have a dedicated COVID-19 section on our website, which is regularly updated as information becomes available.